Latest Posts

  • Finance 0

    Treasury Market’s 10-Year Inflation Forecast Falls To 7-Year Low

    Yesterday’s tumble in US equities fueled another leg down in Treasury yields. As the bear market in stocks rolls on, the crowd continued to rush into the safe-haven trade, pushing the 10-year yield down to 1.75% yesterday (Feb. 8)–the lowest level in about a year, based on daily data via Treasury.gov. Meanwhile, the 2-year yield—considered the most sensitive spot on the yield curve for rate expectations—tumbled to 0.66%, the lowest in nearly four months. The acceleration in the risk-off sentiment is raising more doubts about the Federal Reserve’s previously stated plans to continue raising interest rates this year. Not surprisingl...
    On February 9, 2016 / By
  • Finance 0

    This Is Your Best Investment When The Fed Turns To Negative Interest Rates

    The Dow Jones Industrial Average plunged through the psychologically important 16,000 mark in yesterday’s sell-off, while the S&P 500 and Nasdaq slid 2% and 2.3%, respectively. But in Japan, a Lunar New Year’s treat for investors: The ever-volatile Nikkei 225 snapped a four-day losing streak to end up 1%. That’s performance that most American investors would kill for right now. For that, we can look to Bank of Japan chief Haruhiko Kuroda, a faithful practitioner of the “Abenomics” that have kept Japan’s stock markets curiously (some may say insanely) buoyant in these sell-happy times… only at the...
    On February 9, 2016 / By
  • Finance 0

    E Biocryst Tumbles 71% After Phase 2 Trial Failure

    Yesterday, shares of Biocryst Pharmaceuticals (BCRX) tumbled by 71% after the company had announced that the phase 2 trial failed to produce statistically significant results. The phase 2 trial, known as the OPuS-2 trial, tested the company’s drug BCX4161 — avoralstat — compared to a placebo compound.  A total of 108 patients were recruited for the trial. About 36 patients took 500 mg of avoralstat, 36 patients took 300 mg of avoralstat, and the remaining 36 patients took a placebo compound instead. The primary endpoint of the trial was to see if avoralstat could produce a lower mean attack rate compared to placebo in these...
    On February 9, 2016 / By
  • Finance 0

    EU Bullet Report: JPY And Gold Soar As Asian Markets Collapse

    After a day to forget for the European and US stocks which saw major indices in Europe lose more than 3% and US more than 1.8%, the Asian markets followed in the same path. Japans Nikkei is down 5.41% at time of writing, as the anxiety over slowing growth, falling oil prices (again below $30) and very low interest rates took its toll in investors’ confidence. Some Asian markets including China, Hong Kong, South Korean, Singapore and Taiwan are still in Lunar New Year holiday. The slump in Asia is also caused by a surge of the JPY versus the USD which rose to over a 1 year high which touched 114.20. Rises in the yen make Japanese exports les...
    On February 9, 2016 / By
  • Finance 0

    Europe Stabilizes After Asia Melts

    After a meltdown in Asia, the global capital markets are stabilizing in Europe. The US S&P managed to recoup about half of its losses before the close yesterday, but this gave not comfort to Japanese investors. The yen’s strength and ongoing concerns about banks’ exposure to energy companies took the down 5.4% and pushed the 10-year JGB yield into negative territory for the first time.   The Dow Jones Stoxx 600 is off 0.25% near midday in London. Telecoms and consumer staples are firm, but materials and financials are the largest drags. This plays on the bank-energy theme as well as more concern about European banks. In ...
    On February 9, 2016 / By
  • Finance 0

    Joe Reagor’s Equity Picks For Patient Pickers

    Picking gold and silver equities in a stagnant price environment is a stock picker’s game that requires a particular thesis—and a fair portion of patience, says Joe Reagor, an analyst with ROTH Capital Partners. In this interview with The Gold Report, Reagor outlines types of companies he prefers and pairs those with names that patient investors could parlay into promising profits. The Gold Report: In a report from RBC Capital Markets in late January, the firm said gold could reach as high as $1,200/ounce ($1,200/oz) in the short term but remains in an overall downward trend. Does ROTH Capital Partners share that view? Joe Reagor: ...
    On February 9, 2016 / By
  • Finance 0

    Markets Take Another Hit On U.S. Jobs Data, Oil Weakness

    The U.S. equities market is nearing recession status in 2016, with the S&P 500 down 8% on the year and the Dow Jones Industrial Average and the Nasdaq following suit with 7% and 12.87% declines, respectively. Jobs data Friday’s U.S. jobs report didn’t help either. According to the report, the United States added 151,000 jobs in January, well below the 190,000 target by economists. The unemployment rate dropped to 4.9% from 5%, however. Thus far, the job market has been a boon for the U.S. economy, and it was one of the main reasons the Federal Reserve hiked the federal funds rate in December. So to see that the following month’s re...
    On February 9, 2016 / By
  • Finance 0

    3 Biotech Stocks To Turn The Tide This Earnings Season

    A cloud of uncertainty has engulfed the financial markets as investors the world over have to deal with global macroeconomic challenges led by the China downturn and falling oil prices.  The NYSE ARCA Biotech Index (^BTK) and NASDAQ Biotechnology Index (^NBI) have plunged 26.1% and 21.8% respectively so far this year. The second half of 2015 had seen a huge sell-off in the biotech sector after Democratic Presidential candidate Hillary Clinton’s tweet on price gouging reignited the debate on high prices of drugs. Stocks like Valeant Pharmaceuticals (VRX) were the most impacted losing more than half of their net worth as the company was accu...
    On February 9, 2016 / By
  • Finance 0

    This Is What Central Bank Failure Looks Like

    From omnipotence to impotence… Peter Pan(ic) is here… NKY is 1000 points below pre-NIRP levels and USD/JPY is 4 handles lower (JPY stronger)…   Simply put – not only are words not enough to create the only effect that Central Banks care about, but their actions are now worse than doing nothing… Japanese Bank stocks are down 25% since NIRP was unleashed (and 32% since the start of the year)…  ...
    On February 9, 2016 / By
  • Finance 0

    21st Century Fox Q2 Earnings In Line, Revenues Miss

    After beating the Zacks Consensus Estimate for seven consecutive quarters, Twenty-First Century Fox, Inc. (FOXA – Analyst Report) reported in-line earnings of 44 cents a share in the second quarter of fiscal 2016. However, quarterly earnings declined 17% year over year, disappointing investors. This was clearly reflected in the after-market trading hours yesterday, when shares tumbled 4.4%....
    On February 9, 2016 / By